Changes to Lannett's board
This article was originally published in Scrip
Lannett Company, a generics business, has appointed Ronald West chairman of the board, succeeding William Farber who will take on the role of chairman emeritus. Mr West has been a member of Lannett's boards since 2002 and most recently served as lead director since 2009. Mr Farber has been Lannett's chairman since 1991 and previously served as president and a director of Auburn Pharmaceutical Company.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.